Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

$SONX
Medical/Dental Instruments
Health Care
Get the next $SONX alert in real time by email
SC 13G/A 1 sonx-sc13ga_111424.htm AMENDMENT TO FORM SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934*

 

(Amendment No. 2)

 

Sonendo, Inc.

(Name of Issuer)

 
Common Stock, $0.01 par value

(Title of Class of Securities)

 
835431206

(CUSIP Number)

 
September 30, 2024
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)
     
  Rule 13d-1(c)
     
  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No . 835431206   Page 2 of 7

 

1

NAME OF REPORTING PERSONS
First Light Asset Management, LLC

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY)

46-3521994

 
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3 SEC USE ONLY  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON
WITH:

5

SOLE VOTING POWER

0

 
6

SHARED VOTING POWER

0

 
7

SOLE DISPOSITIVE POWER

0

 
8

SHARED DISPOSITIVE POWER

0

 
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

 
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.0%

 
12

TYPE OF REPORTING PERSON

IA

 
         

 

 

 

CUSIP No . 835431206   Page 3 of 7

 

1

NAME OF REPORTING PERSONS
Mathew P. Arens

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY)

 
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3 SEC USE ONLY  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United State of America

 

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON
WITH:

5

SOLE VOTING POWER

30

 
6

SHARED VOTING POWER

3,611

 
7

SOLE DISPOSITIVE POWER

30

 
8

SHARED DISPOSITIVE POWER

3,611

 
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,641

 
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.99%

 
12

TYPE OF REPORTING PERSON

IN

 
         

 

 

 

CUSIP No. 835431206   Page 4 of 7

 

Item 1(a). Name of Issuer:
  Sonendo, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
  26061 Merit Circle, Suite 102, Laguna Hills, CA 92653
   
Item 2(a). Name of Person Filing:
 

This Schedule 13G is being jointly filed by the following:

 

First Light Asset Management, LLC (the “Manager”)

Mathew P. Arens (“Mr. Arens”)

 

 

The Manager may be deemed to be the beneficial owner of 0 of the Issuer’s shares of common stock (the “Shares”). The Manager may be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. Mr. Arens also directly holds 30 shares in an individual capacity with sole control. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act. The amounts reported assume the exercise of 3,611 warrants by Mr. Arens, and if not for the blocker, the reporting persons would have the ability to exercise an additional 5,608 warrants in the aggregate.

 

The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

   
Item 2(b). Address of Principal Business Office or, if None, Residence:
 

Each of the reporting persons identified in Item 2(a) has its principal business office at:

 

3300 Edinborough Way, Suite 201, Edina, MN 55435

   
Item 2(c). Citizenship:
 

First Light Asset Management, LLC – Delaware limited liability company

Mathew P. Arens – United States citizen

   
Item 2(d). Title of Class of Securities:
  Common Stock, $0.01 par value
   
Item 2(e). CUSIP Number:
  835431206
   
Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
     
  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

 

 

 

CUSIP No . 835431206   Page 5 of 7

 

  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
       
  (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
       
  (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).
       
Item 4. Ownership.
   
  Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
   
  (a) Amount beneficially owned:
   

First Light Asset Management, LLC – 0

Mathew P. Arens – 3,641

     
  (b) Percent of class:
   

First Light Asset Management, LLC – 0.0%

Mathew P. Arens – 0.99%

 
  (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
     

First Light Asset Management, LLC – 0

Mathew P. Arens – 30

       
    (ii) Shared power to vote or to direct the vote
     

First Light Asset Management, LLC – 0

Mathew P. Arens – 3,611

       
    (iii) Sole power to dispose or to direct the disposition of
     

First Light Asset Management, LLC – 0

Mathew P. Arens – 30

       
    (iv) Shared power to dispose or to direct the disposition of
     

First Light Asset Management, LLC – 0

Mathew P. Arens – 3,611

 

 

 

 

CUSIP No . 835431206   Page 6 of 7

 

Item 5. Ownership of Five Percent or Less of a Class.
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
  Not applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
  Not applicable
   
Item 8. Identification and Classification of Members of the Group.
  Not applicable
   
Item 9. Notice of Dissolution of Group.
  Not applicable
   
Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

FIRST LIGHT ASSET MANAGEMENT, LLC

   
  Date: November 14, 2024  
       
  By: /s/ Kurt T. Peterson  
  Name: Kurt T. Peterson  
  Title: Chief Compliance Officer  
   
   
 

Date: November 14, 2024

 
 
  Signature: /s/ Mathew P. Arens  
  Name: Mathew P. Arens  

 

 

Get the next $SONX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SONX

DatePrice TargetRatingAnalyst
3/12/2024Buy → Hold
Stifel
1/31/2022$6.90Equal-Weight
Morgan Stanley
11/23/2021$16.00Buy
Stifel
11/23/2021$15.00Buy
B of A Securities
11/23/2021$30.00Buy
Goldman Sachs
11/23/2021$17.00Overweight
Piper Sandler
More analyst ratings

$SONX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo, Inc. Reports Third Quarter 2024 Financial Results

    Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

    $SONX
    Medical/Dental Instruments
    Health Care

$SONX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SONX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SONX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SONX
SEC Filings

See more

$SONX
Leadership Updates

Live Leadership Updates

See more
  • Sonendo Strengthens Leadership With Key Strategic Appointments

    John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

    The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

    Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

    $SONX
    Medical/Dental Instruments
    Health Care

$SONX
Financials

Live finance-specific insights

See more
  • Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

    $SONX
    Medical/Dental Instruments
    Health Care
  • Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

    Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

    $SONX
    Medical/Dental Instruments
    Health Care

$SONX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more